Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28484685 | 1.00 | NPC1 (0.61) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28674499 | 0.87 | NPC1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27865678 | 0.87 | NPC1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19010019 | 0.87 | NPC1 (0.72) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19010013 | 0.85 | NPC1 (0.74) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20259264 | 0.81 | NPC1 (0.60) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20634694 | 0.77 | NPC1 (0.56) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7176793 | 0.77 | NPC1 (0.67) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31048501 | 0.77 | NPC1 (0.67) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15883113 | 0.77 | NPC1 (0.67) | NPC1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106660996-B | 2, 5-substituted pyrimidines as PDE4 inhibitors | 格吕伦塔尔有限公司 | 2020-10-16 | — | — | CN | disclosed |